Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Predicting response to trastuzumab deruxtecan may be changing.
HER2 IHC categories may not fully predict who benefits from T-DXd.
Emerging evidence suggests that quantitative HER2 biology, rather than categorical IHC classification, may better explain treatment response.
Methods highlighting this concept include:
- High-sensitivity HER2 protein quantification
- RPPA-based proteomic HER2 measurement
- ERBB2 mRNA expression analysis
- HER2 copy number / amplicon assessment (NGS)
- Plasma-based DNA assays
In the era of ADCs, HER2 may not be a category – it may be a continuum.”
Title: Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
Authors: Paolo Tarantino, Se-Eun Kim, Melissa E. Hughes, Ross J. Kusmick, Kalie Smith, Fara Brasó-Maristany, Nay Nwe Nyein Chan, Laia Paré Brunet, Laura Alder, Diana Garcia-Cortes, Jorge Gomez Tejeda Zanudo, Alyssa M. Pereslete, Laura Noteware, Heather Moore, Amanda E. D. Van Swearingen, Tianyu Li, Hersh Gupta, Olivia D’Amico, Alba Martini, Stefania Morganti, Jennifer Spindel, Charmaine Cook, Christine McLaughlin, Kathrin Dvir, Ana C. Garrido-Castro, Sarah Sammons, Janet Files, Kerry Sendrick, Simone Buck, Deborah Dillon, Rinath Jeselsohn, Yvonne Y. Li, Andrew D. Cherniack, Patricia LoRusso, Maryam Lustberg, Rosario Vega- León, Francisco Pardo, Justin Davis, Claudius Mueller, Brian Corgiat, Giuseppe Curigliano, Carey K. Anders, Emanuel F. Petricoin, David L. Rimm, Aleix Prat, Nabihah Tayob, Nancy U. Lin and Sara M. Tolaney.
Other articles featuring Ahmet Dirican on OncoDaily.